Related Experiment Video
Updated: Aug 10, 2026

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
Published on: July 11, 2015
Long-term therapy with rifampin and the secondary antibody response to killed influenza vaccine
Abstract:
The secondary antibody response was studied in 22 patients with tuberculosis, 11 of whom were taking rifampin as part of their antituberculous regimen. The mean duration of rifampin therapy was 12.7 months. Hemagglutination-inhibiting antibody titers to bivalent influenza vaccine were determined before, and 4 and 8 weeks after, vaccination. There was no significant difference in the number of patients who developed a 4-fold or greater increase in titer, or in the level of titer response between the rifampin and control groups. Long-term therapy with rifampin was not found to suppress the secondary antibody response to influenza vaccination.
Related Concept Videos
Vaccinations
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Rocky Mountain Spotted Fever
Smallpox
Respiratory Syncytial Virus Disease

